0.1 ml of Semaglutide: Clearing Up a Common Confusion

The misconception: that 0.1 ml is a dose you dial or draw up

The most common reason people search for 0.1 ml semaglutide is an encounter with content about injectable medicines that mix milligrams with millilitres as though they are interchangeable. They are not. Milligrams measure the amount of active drug; millilitres measure volume of solution. For a licensed medicine like Wegovy, those two numbers are linked by the product's concentration, which is fixed by the manufacturer and matters to pharmacists checking supply, not to patients adjusting their own pens.

Wegovy's pre-filled KwikPen delivers one fixed weekly dose with each click. There is no plunger to pull back, no syringe to fill, and no volume for you to calculate. If you have seen instructions describing 0.1 ml as a starting amount to draw into a syringe, that content almost certainly refers to a compounded or unlicensed preparation, not to a product that holds a UK marketing authorisation for weight management.

It's understandable to feel uncertain when different sources use different units. Dosing information online can be fragmented, contradictory, and sometimes genuinely about products that aren't legally available in the UK at all. If you're questioning what your pen actually delivers, the right place to clarify is with a prescriber, not a search engine.

How semaglutide concentrations actually work in licensed products

Each Wegovy pen contains semaglutide in solution at a defined concentration. The pen's mechanism is calibrated to release exactly the right volume to deliver your prescribed milligram dose. For example, the 0.25 mg/dose pen and the 2.4 mg/dose pen contain semaglutide at concentrations that produce the correct dose in a controlled, sealed injection, with no patient involvement in volume management.

Where a concentration expressed as mg/ml becomes relevant is in clinical and pharmacy documentation: checking supply, verifying a prescription, or cross-referencing the Summary of Product Characteristics. You can review the precise concentrations and solution volumes in the Wegovy SmPC listed on the electronic Medicines Compendium, which is a useful reference if a healthcare professional asks you about your medicine, but it is not a guide to self-dosing.

The NHS guidance on semaglutide is clear that patients follow their prescriber's instructions and the Patient Information Leaflet, both of which describe when to inject and general technique, never a volume to measure. Our Wegovy treatment page covers the licensed dose pathway in plain terms.

Compounded semaglutide and why the volume question matters most there

The 0.1 ml figure appears most frequently in the context of compounded semaglutide products circulating online and on social media. Compounded preparations are not MHRA-licensed medicines: they are prepared outside the regulated manufacturing process, with variable concentrations, and are often sold alongside instructions to draw up a specific volume from a vial using a syringe. That's where the millilitre calculation becomes a patient-level concern, and it is also where the risks are concentrated.

In the UK, Wegovy and the wider semaglutide products licensed for weight management are supplied as single-use, pre-dosed, sterile pens from Novo Nordisk. No UK-licensed semaglutide product for weight loss requires patients to measure 0.1 ml (or any other volume) themselves. The MHRA has issued repeated warnings about unlicensed weight-loss products sold online; the Yellow Card scheme exists partly so patients and healthcare professionals can report suspect products.

If cost is the reason you've been researching alternatives, our page on the costs and options within a regulated private pathway explains what a legitimate prescription service includes. A private consultation through a GPhC-registered pharmacy is considerably safer than an unlicensed preparation at any price point.

What a legitimate semaglutide prescription actually looks like

A legitimate Wegovy prescription in the UK names the dose in milligrams, the frequency (once weekly), and the injection route (subcutaneous). Your prescription will not mention a volume to draw up. The pen you receive is pre-filled and pre-set. You inject subcutaneously into your abdomen, thigh, or upper arm, rotate sites weekly, and that's the extent of the manual process.

The licensed titration schedule starts at 0.25 mg weekly for four weeks, moving through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose. Each step in that journey corresponds to a specific pen size, and you can read about how the pen volumes relate to each stage on our pages covering 1 ml semaglutide, 2 ml semaglutide, 3 ml semaglutide, and 5 ml semaglutide. MHRA approval of a 7.2 mg pen (granted on 14 April 2026) extends the ceiling further; any movement to that level is a clinical decision made with a prescriber, not a self-selected step. For context on how results from the STEP 1 trial informed the licensed pathway, the STEP 1 study in the New England Journal of Medicine remains the primary published evidence base.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. You can read about our clinical team on the clinical team page. Our semaglutide overview gives broader context on who this medicine is for, and if you have further questions our team is reachable via the contact page.